AI Summary
✦ ClarthaBliss GVS Pharma is a pharmaceutical formulations company serving Indian and international markets. Its revenue spans anti-diabetic, anti-infective, and gastrointestinal products, alongside dermatology, respiratory, and pain-management offerings. Exports broaden market reach, while the portfolio supports 14.8% year-on-year revenue growth. No major recent development provides a clear incremental catalyst for margins or growth. Profit increased 53.2% year-on-year as margins improved, but 11.6% ROE remains moderate. Debt/equity of 1.77 indicates leverage is materially supporting ROE and increases financial risk. At 39.8x earnings, the stock appears rich relative to its growth profile, despite accelerating profit. The key open question is whether margin improvement can persist while leverage remains elevated.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 68 using EVA spread proxy -0.4%; growth durability 100.0.
Valuation
Valuation institutional score is 0 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 72 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
This data source has not been supplied for the decision payload.
Signal Summary
Market intelligence remains Mixed. fundamentals and technical structure provide support, while valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 271.2% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +3.37). Confidence: 50%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
11.75
Current
41.17
Overvalued
13.71
Undervalued
9.73
5Y Average
8.92
Current
31.26
Overvalued
9.83
Undervalued
4.98
5Y Average
1.62
Current
5.66
Overvalued
1.78
Undervalued
0.90
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
GRANULES INDIA LIMITED GRANULESPharmaceuticals | +22.0% | 11.8% | 32.7x Fair | -11% vs avg | +87.9% |
ALEMBIC PHARMA LTD APLLTDPharmaceuticals | +25.7% | 8.9% | 23.7x Undervalued | -36% vs avg | -12.4% |
BATA INDIA LTD BATAINDIAFootwear | +5.0% | 3.8% | 67.6x Premium | +84% vs avg | -37.2% |
AARTI INDUSTRIES LTD AARTIINDSpecialty Chemicals | +42.5% | 5.9% | 34.6x Fair | -6% vs avg | +35.0% |
ATUL LTD ATULDiversified Chemicals | +25.0% | 12.0% | 25.3x Undervalued | -31% vs avg | +5.0% |
BLISS GVS PHARMA LTD trades in line with peers (41.2x vs avg 36.8x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include GRANULES INDIA LIMITED, ALEMBIC PHARMA LTD, BATA INDIA LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹212 CrMar 2026Latest net profit
₹32 CrMar 2026Latest EPS
₹3.06Mar 2026Net margin
21.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 143 | 109 | 171 | 161 | 164 | 149 | 183 | 180 | 156 | 163 | 190 | 165 | 212 |
| Expenses + | 133 | 98 | 129 | 133 | 139 | 122 | 157 | 154 | 142 | 131 | 160 | 138 | 167 |
| Operating Profit | 11 | 11 | 42 | 29 | 25 | 27 | 25 | 26 | 14 | 33 | 30 | 27 | 44 |
| OPM % | 8% | 10% | 25% | 18% | 15% | 18% | 14% | 14% | 9% | 20% | 16% | 16% | 21% |
| Other Income + | 6 | 7 | 11 | 8 | -33 | 7 | 8 | 12 | 9 | 11 | 14 | 8 | 10 |
| Interest | 5 | 1 | 1 | 2 | 2 | 1 | 3 | 1 | 1 | 5 | 3 | 1 | 2 |
| Depreciation | 4 | 5 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 8 | 8 | 8 | 8 |
| Profit before tax | 8 | 11 | 46 | 29 | -15 | 26 | 24 | 30 | 14 | 31 | 33 | 25 | 44 |
| Tax % | 28% | 31% | 26% | 27% | -25% | 26% | 29% | 29% | 20% | 31% | 26% | 26% | 27% |
| Net Profit + | 6 | 8 | 34 | 21 | -11 | 19 | 17 | 21 | 11 | 21 | 25 | 19 | 32 |
| EPS in Rs | 0.59 | 0.72 | 3.25 | 1.98 | -1.09 | 1.85 | 1.62 | 2.00 | 1.09 | 2.00 | 2.35 | 1.76 | 3.06 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday, August 12, 2026
Pre-Offer Advertisement & Corrigendum to Detailed Public Statement